**Cost-effectiveness of screening mammography in a low income country: a Markov simulation analysis**

Segni Kejela*

**Abstract**

**Background:** Breast cancer is the most common cancer diagnosed in women. Screening mammography is the only imaging screening study for breast cancer with a proven mortality benefit. This study aims to analyze the cost-effectiveness of screening mammography in Ethiopia.

**Methods:** Multistate Markov model was used for computer simulation to estimate cost and health benefits of screening mammography interventions for age-group of 40–49 years and 50–59 years. The cost-effectiveness analysis was made for 4 policies based on where the screening mammography procedures were conducted: government institution only, the private institution only, 50% ratio for each, and 10% private institution policy. Outputs were expressed in total cost, life-years gained (LYG) incremental cost-effectiveness ratio (ICER), and incremental net monetary benefit (INMB).

**Results:** All 4 policies of annual screening mammography failed to achieve acceptable ICER and lead to a net loss in INMB. The lowest ICER value was for government institution-only policy with 3510.3 USD/LYG and 3224.9 USD/LYG both above the cost-effectiveness threshold of 2808.5 USD. The cost per single death averted for each group was 110,206.7 USD and 77,088.2 USD for age-group 40–49 years and 50–59 years respectively.

**Conclusion:** Screening mammography could not be shown to be cost-effective in Ethiopia with the current low cost-effectiveness threshold. Alternative screening approach like annual clinical breast examination may need to be investigated.

**Keywords:** Markov multistate analysis, Low income countries, Screening mammography

**Introduction**

Breast cancer is the most common cancer among women worldwide. Globally breast cancer contributes to 24.2% of all cancer diagnoses and 15% of cancer mortality [1, 2]. Majority of this burden occurs in low and middle-income countries with more than 60% global annual mortality being recorded in this segment of the world with the reported highest mortality rate from Africa [3, 4]. This is likely from poor resources and manpower compounded by the delay in presentation and confounding traditional factors [5, 6].

Screening mammography is the only imaging screening study for breast cancer with a significant mortality benefit that the National Comprehensive Cancer Network (NCCN) has put forward as a category 1 protocol for patients with average risk with age 40 years or above [7, 8]. Similar clinical practice guidelines have been published from eastern countries with similar annual mammography screening recommendations though few maintained biennial frequency [9, 10].

*Correspondence: segnikejo@gmail.com*

College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
African nations’ recommendations are generally lacking even in more developed countries like South Africa [11]. Considering lower median age at diagnosis in the Sub-Saharan African population of breast cancer patients with possibly higher resultant aggressive nature of breast cancer in young, it seems imperative to look into the possibility of screening mammography from 40 years onwards [12, 13].

In Ethiopia as in all African nations, no national breast cancer screening program is present. Nationally mammography services are available, albeit not widespread, both in governmental and private health institutions. No national data is to date available on the proportion of breast cancer patients diagnosed with screening mammography and the number of patients currently enrolled in the screening program. Additionally, the cost-effectiveness and feasibility of a national breast cancer screening program have not been studied in Ethiopia or African nations. This study aims to analyze the cost-effectiveness of the annual national screening mammography program for all Ethiopian women age 40 years and above.

Methods
Method description
Screening mammography is used to detect breast cancer at an earlier stage than the non-screened population group. Screening mammography has age-specific sensitivity and specificity, so there are a group of patients diagnosed with symptoms as in a non-screened population while on screening protocol and likewise, some patients will undergo diagnostic tests because of false-positive screening mammography results. All diagnosed breast cancer patients undergo treatment based on their respective stage, grade, the genetic and immunochemical status of the tumor. All these steps result in predictable cancer progression stages on which simulation models can be conducted (Fig. 1).

Age categories of 40–49 years and 50–49 years were chosen and the assumption of 100% participation in the screening program was made for the simulation. The age group 30–39 years were excluded because of the absence of validated screening protocol in this age group and the age group 60–69 years were excluded because of the lower life expectancy of the Ethiopian population and resultant lower contribution to the overall population number [13]. The cost and death averted by screening were compared to the population with no screening. All women suspected of breast cancer from the screening group had incurred additional costs of the diagnostic test. Diagnostic test of FNAC was chosen for all suspected and for all non-screened patients as core needle biopsy is not widely available in Ethiopia. All screening or non-screening detected breast cancer cases were assumed to have undergone proper treatment for the respective stages. Women in each of diagnosed breast cancer were enrolled into the Markov chain extended from the decision tree (Fig. 2).

The Multi-state Markov model was used for analysis to incorporate multiple states of the output of health states. 5 states were chosen, Remission, local recurrence,
distant recurrence, death from breast cancer, and death from other causes. Local and distant recurrences were assumed to remain in the same stage or progress. Outputs for the models were, cost, life years, cost per death averted, and the number of women screened for death averted (Fig. 2).

**Model inputs**

**Epidemiologic inputs**

Table 1 depicts all essential inputs used in this model. Age distribution of breast cancer was extrapolated from the proportion of breast cancer patients by age group from Kantelhardt et al. and extrapolated to the whole population from both the national population proportions and WHO cancer data for breast cancer for Ethiopia, and the final output of breast cancer incidence was calculated and presented [13, 14]. The transition between health states for breast cancer is not available for Ethiopia, and Gocgun et al. data from their Markov model was utilized [15]. All patients, screened or non-screened diagnosed with breast cancer were assumed to have the same transition probabilities.

There is no publication available on breast cancer screening in Ethiopia. For this reason, screening mammography sensitivity and specificity for age were extracted from Keen et al. for both age groups [16]. In certain occasions of uncertainties in the images, a fuzzy preprocessing would be necessary [20]. Similarly, stages at diagnosis of breast cancer for a screening-detected group of patients were not nationally available and was extrapolated from the Chinese screening program [17]. But, stage at diagnosis for non-screened patients for Ethiopia was available from Tesfaw et al. [18].

The price for mammography and FNAC is set by institutions in both private and government institutions. For this reason, both major government and private institutions were communicated and the mean reported prices for each category of service were used and translated to United States Dollars (USD).

Treatment cost was only available in the form of cost per patient treated for breast cancer in an Ethiopian oncology center with no Stage-specific report. With the cost of 893 USD in direct medical costs, and accounting for a higher stage III proportion of patients in the Ethiopian non-screened group, the medical costs of Stage III breast cancer from the Vietnam study were well nearly equal to the average cost of breast cancer treatment in Ethiopia. So, the price report of Hoang Lan and colleagues was utilized for estimating the treatment price [19, 21].

WHO life tables used for expected life years loss and gain analysis for each age-group category specific to Ethiopia [22]. Discount rates of 5% for cost and 3% for life years were used for this model.

**Outputs**

The two price points were analyzed separately first for total cost and final incremental cost-effectiveness ratio (ICER). Then assumption was made in which the two institutions shared 50% of screening mammography
and similarly total cost and ICER was again calculated. A similar model was generated for a government-dominated screening with 90% and the rest 10% screened at a private institution. Total life-years gained from screened, the number of cancer screened to avert one death, and cost per death averted were calculated for

| Table 1 | Essential inputs for the model |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Name**        | **Live value**  | **Distribution** | **Reference**   |
| Age distribution of Breast cancer | | | |
| 30–39           | 0.000853        | Beta            | Kantelhardt, et al. [14] |
| 40–49           | 0.000878        | Beta            | Gocgun et al. [15] |
| 50–59           | 0.00079         | Beta            | Keen et al. [16] |
| 60–69           | 0.000656        | Beta            | Wong et al. [17] |
| Stage progression transition probabilities | | | |
| Stage I         | Age 40–49       | Age 50–59       | Beta            | Tesfaw et al. [18] |
| Remission to local recurrence | 0.01 | 0.009 |
| Remission to distal recurrence | 0.000016 | 0.00025 |
| Local recurrence to distal recurrence | 0.062 | 0.052 |
| Local recurrence to cancer death | 0.013 |
| Distal recurrence to cancer death | 0.555 | 0.137 |
| Stage II & III | | | |
| Remission to local recurrence | 0.018 | 0.016 |
| Remission to distal recurrence | 0.024 | 0.105 |
| Local recurrence to distal recurrence | 0.165 | 0.13 |
| Distal recurrence to cancer death | 0.386 | 0.423 |
| Stage IV        | Distal recurrence to cancer death | 0.386 | 0.423 |
| Mammography sensitivity and specificity (40–49, 50–59 years) | | Beta | Keen et al. [16] |
| Sensitivity | 0.821, 0.921 |
| Specificity | 0.859, 0.859 |
| Breast cancer stage distribution, screened | | MBT | Wong et al. [17] |
| Stage I | 0.521 |
| Stage II | 0.382 |
| Stage III | 0.057 |
| Stage IV | 0.041 |
| Breast cancer stage distribution, Non-screened | | MBT | Tesfaw et al. [18] |
| Stage I | 0.1 |
| Stage II | 0.189 |
| Stage III | 0.569 |
| Stage IV | 0.143 |
| FNAC(USD) | 22 | Invariant | Personal communication |
| Cost of mammography(USD) | | Invariant | Personal communication |
| Government Institutions | 4.5 |
| Private institutions | 42 |
| Doctor visit cost | 6 |
| Treatment cost(USD) | | Gamma | Hoang Lan, et al. [19] |
| Stage I | 160 |
| Stage II | 458.48 |
| Stage III | 850.45 |
| Stage IV | 668.7 |
| Expected life, 40–44 | 36.10367697 | Gamma | World Health Organization [19] |
| Expected life, 45–49 | 31.72113989 | Gamma | World Health Organization [19] |

FNAC fine-needle aspiration cytology, MBT multivariate beta distribution, USD United States Dollars
each price category. Specific willingness to pay amount has not been set for screening mammography in Ethiopia. The mammography screening is considered cost-effective if the ICER was less than 3 times the GDP per capita according to the WHO recommendation which was determined to be 2808.9 USD from the 2020 world bank report [23, 24]. Incremental net monetary benefit (INMB) was calculated for ICER outputs that are found to be less than a willingness to pay threshold (3*GDP per capita).

Sensitivity analysis
One-way sensitivity analysis was done using all likely parameters, and values that affected the output were presented on a tornado plot for both age groups analyzed in this model. Second-order Monte Carlo simulation was conducted using 10,000 iterations. All values except discount rates were set to have low and high values of 20% less or more than the base case values respectively because of conclusive data for specific value ranges. Discount rates lowest range of 0% and high value of 6% were utilized for sensitivity analysis.

Ethical considerations
This is a simulation analysis involving no human or animal subjects. Only publicly accessible information was utilized for the simulation creation. With no human subject involved the study is not subject to any ethical consideration from Helsinki declarations and National Health Research Guidelines.

Results
Table 2 summarized the three screening policies separately with the respective total cost, ICER, life-years gained, cost per death averted and number screened per death averted. All results on the table are presented per 100,000 women over 10 year period. The standard errors of total costs were 751.41 and 762.720 for age-group 40–49 years and 50–59 years respectively. 78.55 and 107.38 deaths were averted for age group 40–49 years and 50–59 years respectively from screening mammography. The gain in life years from screening were 2466.14 years and 2566.93 years respectively for the age group of 40–49 years and 50–59 years.

All the policies evaluated the only policy for both age-groups the ICER value was above willingness to pay threshold with government institution screening mammography only policy yielding the lowest ICER value of 3510.275 and 3224.87 for age-group of 40–49 years and 50–59 years respectively. The lowest INMB loss was recorded in the government-only policy with $−1,730,678.81 USD and $−1,068,815.095 USD for age-group 40–49 years and 50–59 years respectively. The lowest INMB value were $4,842,560.81 USD and $4,099,517.1 USD showing a net monetary loss.

Cost per life years gained were $110,206.7 USD/death averted and $77,088.2 USD/death averted for the age group of 40–49 years and 50–59 years respectively for government only policy. 1273.06 patients had to be screened to avert one death for the age group of 40–49 years of age.

Table 2 Results for life-years gained and cost–benefit analysis with the different costs for mammography

| Category                                      | Total cost (USD) | YLG  | ICER        | Cost/death averted | Number screened/death averted |
|-----------------------------------------------|------------------|------|-------------|--------------------|-------------------------------|
| The private institution only screening mammography |                  |      |             |                    |                               |
| Age 40–49 years                               | 38,967,374       | 2466.14 | 15,800.95  | 496,078.17         | 1273.06                       |
| Age 50–59 years                               | 38,585,063       | 2566.93 | 15,031.6    | 359,319            | 931.238                       |
| Government institution only screening mammography |                  |      |             |                    |                               |
| Age 40–49 years                               | 8,656,833        | 2466.14 | 3510.275   | 110,206.7          | 1273.06                       |
| Age 50–59 years                               | 8,278,038        | 2566.93 | 3224.87    | 77,088.2           | 931.238                       |
| Screening mammography with 50% of women screened at government and 50% at a private institution |                  |      |             |                    |                               |
| Age 40–49 years                               | 24,014,173       | 2466.14 | 9737.55    | 305,714.92         | 1273.06                       |
| Age 50–59 years                               | 23,633,597       | 2566.93 | 9206.93    | 220,085            | 931.238                       |
| Screening mammography with 90% of women screened at government and 10% at a private institution |                  |      |             |                    |                               |
| Age 40–49 years                               | 11,768,715       | 2466.14 | 4739.343   | 148,793.85         | 1273.06                       |
| Age 50–59 years                               | 11,308,740       | 2566.93 | 4405.54    | 105,311.26         | 931.238                       |

YLG: years of life gained, ICER: incremental cost-effectiveness ratio, USD: United States Dollars
with a lower number required, 931.238, for the age group of 50–59 years.

**Probabilistic sensitivity analysis**

One-way sensitivity analysis was done using ICER as an output for both age groups with a government price policy and the values were presented in a tornado plot. (Figs. 3, 4) For both age categories, the price of screening mammography along with doctor visits and sensitivity of the screening mammography had the highest impact on output. The range of ICER for one-way sensitivity of the cost of mammography is 2822 to 4198.55 and for the sensitivity of the screening mammography was 3129.95 to 3991.5 for the age group of 40–49 years. The same effect is seen in the age group 50–59 years, with a range from one-way sensitivity analysis using the cost of mammography of 2563.7 to 3886.05, and for the sensitivity of the screening mammography, range of 2762.4 to 3866.9.

Different transition states for both age groups were evaluated and were found to affect ICER only in distant recurrence to death transition for stage III and IV in age-group of 50–59 years, and distant recurrence for stage III and IV, also local to distal recurrence transition for the age group between 40 and 49 years.

**Discussion**

In this Markov simulation, annual mammography utilizing all four policies with an out-of-pocket payment plan was not shown to be cost-effective with INMB projecting net loss consistently. It required close to 110,206.7 USD and 77,088.2 USD to avert one death in each group of 40–49 years and 50–59 years respectively with the cheapest policy. Close to 1270 and just more than 930 women need to be screened to avert one death for age-group 40–49 years and 50–59 years respectively. The ICER was most affected by the price and the sensitivity of the screening mammography study. It is worth noting that 100% sensitivity for both age groups can theoretically yield acceptable cost per life years gained of 2527 and 2736 for age-group 40–49 years and 50–59 years respectively.

Except for Rwanda and Ghana, most African countries have no universal health care coverage despite the urge from WHO to progress away from service users out of pocket fees [25]. Ethiopia, like most African nations also, largely relies on out-of-pocket payment for health care services [26]. For this reason, screening mammography policies for the time being need to rely on an out-of-pocket payment plan.

Health care facilities in Ethiopia have significantly different price ranges based on the purpose of their establishment and the organization running the individual institutions. Price range increases progressively from Government Hospitals, Non-profit organizations, and finally private full profit health care institutions [27]. For this reason, separate simulations were required to analyze the possibility of private health sector involvement in the screening mammography policy and whether it is possible to achieve cost-effectiveness with either full,
partial, or minimal involvement of the private sector in the screening program.

Costs per life years gained of this study with the use of 100% of private institutions with no government health facility involvement, 15,800.9 USD and 15,031.6 USD per life years gained were too high from a willingness to pay threshold. Understanding the underlying problem would be required to fully understand the output. First, similar studies have shown that these ICER values are not too high for annual screening mammography as the cost per life-years saved could range from 3400 USD to 83,830 USD based on institutions, regions, and countries of interest where the models were designed for [28]. Second, the price range of private health institutions, 42 USD, was not high as shown by a similar study from Canada, with a mean price of 150 USD and 137 USD in the US [15, 29]. Third, the GDP per capita of Ethiopia is very low and the cost-effectiveness ceiling has become too low to allow for a cost range of any amount as evidenced by negative INMB value even when the contribution of the private sector was reduced to only 10% in these models. So, the cost-effectiveness of screening mammography in any of the policies was not inherently ineffective, but rather relatively, and is likely to change with the change in the economy.

Government institutions only screening policy was the closest to favorable ICER with better value for age-group 50–59 years. This owed to the higher sensitivity of the test in the older age group compared to the younger cohort and is consistent with similar models done elsewhere [18]. In Sub-Saharan Africa, women may benefit more from younger age initiation of screening policy as, by the age of 50 years, most breast cancer cases have already been clinically diagnosed [7, 12, 13, 18]. In fact, one major drawback of any validated screening program is the higher younger patient proportion of breast cancer cases in low-income setups at the age younger than 40 years of age where validated screening protocol is lacking [7, 13, 18]. This would especially be unfavorable for Ethiopia where more than 50% of breast cancer patients were found to be younger than 40 years of age [18]. In the younger population with a high risk of breast cancer, like BRCA mutation, the American Cancer Society recommends MRI along with mammography annually [30]. This obviously would be an unlikely alternative for average-risk group women owing to its high cost. Thus, for the age group below 40 years, a validated screening mechanism is needed on which a model can be generated for cost-effectiveness analysis.

This model intentionally omitted clinical breast examination, though it is a cheaper and more available alternative to screening mammography. The first reason for the omission was its notoriously low sensitivity at 54% [31]. Second, to date there is no evidence of its effect on reducing breast cancer-related mortality [32]. To this effect clinical breast examination is not recommended as a routine screening protocol by the American Cancer Society [30]. But with further study and validation for younger than 40 years of age women, annual clinical breast examination can be evaluated for its cost-effectiveness utilizing similar models.

Conclusion

With the current cost of mammography in all policies evaluated using government and private institution prices of mammography, the life-years gained and the deaths averted could not justify the cost of screening mammography in Ethiopia. But with the development of the country, the GDP is expected to increase as well as the cost-effectiveness ceiling. For this reason, revisiting this model may be required and might reach a favorable conclusion. Furthermore, this model may achieve cost-effectiveness in some African countries with better GDP per capita and similar incidence of breast cancer provided that either health insurance is available or governmental subsidy is being implemented.

Acknowledgements

All data acquired from publicly available pieces of literature.

Authors’ contributions

The principal Author conducted the whole study. All authors read and approved the final manuscript.

Funding

No funding was acquired for this study from any private or governmental organization.

Availability of data and materials

Source data will be available upon reasonable request to the corresponding author.

Declarations

Ethical considerations

This is a simulation analysis involving no human or animal subjects. Only publicly accessible information was utilized for the simulation creation. With no human subject involved the study is not subject to any ethical consideration from Helsinki declarations and National Health Research Guidelines.

Consent to participate

Since this study is a Markov simulation analysis, no individual patient data was gathered. For this reason consent to participate is not applicable here.

Consent for publication

Not applicable to this study.

Competing interests

There is no financial and non-financial conflict of interest to declare for this study.
References
1. IA for R on C (IARC). Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. CA Cancer J Clin. 2008;63(September):13–5.
2. American Cancer Society. Global cancer facts & figures. 4th ed. Atlanta: American Cancer Society; 2018. p. 1–76.
3. Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: opportunities for improved survival. J Oncol. 2010. https://doi.org/10.1155/2010/595167.
4. Azebuike SO, Murihead C, Hayes L, McNally R. Rising global burden of breast cancer: the case of sub-Saharan Africa (with emphasis on Nigeria) and implications for regional development: a review. World J Surg Oncol. 2018;16(1):1–13. https://doi.org/10.1186/s12957-018-1345-2.
5. Ibrahimm NA, Oludara MA. Socio-demographic factors and reasons associated with delay in breast cancer presentation: a study in Nigerian women. Breast. 2012;21:416–8.
6. Duffy S, Vulkann D, Cuckle H, et al. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT. Southampton (UK): NIHR Journals Library; 2020 Oct. (Health Technology Assessment, No. 24.55.). Available from: https://www.ncbi.nlm.nih.gov/books/NBK563627/. doi:https://doi.org/10.3310/hta24550.
7. National Clinical Practice Guideline in Oncology (NCCN Guidelines). Breast cancer screening and diagnosis. http://www.NCCN.org. Accessed 15 Aug 2021.
8. Guidance on screening and symptomatic breast imaging, 4th ed. Royal College of Radiologists, 2019.
9. Lee EH, Park B, Kim NS, et al. The Korean guideline for breast cancer screening. J Korean Med Assoc. 2015. https://doi.org/10.5124/jkma.2015.58.S5.408.
10. Hamashima C, Hattori M, Honjo S, et al. The Japanese guidelines for breast cancer screening. Jpn J Clin Oncol. 2016;46(5):482–92. https://doi.org/10.1093/jco/ovy098.
11. Joko-Fru WY, Miranda-Filho A, Soerjomataram I, et al. Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: a population-based registry study. Int J Cancer. 2019;146:1208–18.
12. Verdel FC, Etzioni R, Duggan C, Anderson BO. Demographic changes in breast cancer incidence, stage at diagnosis, and age-associated with population-based mammographic screening. J Surg Oncol. 2017;115(S):517–22.
13. Population pyramids of the world from 1950–2010: Ethiopia. 2020. https://www.populationpyramid.net/ethiopia/2020/. Accessed 11 Aug 2021.
14. Kantelehardt EJ, Zerche P, Mathewos A, et al. Breast cancer survival in Ethiopia: a cohort study of 1,070 women. Int J Cancer. 2014;135:702–9.
15. Golgun Y, Bajevic D, Taghipour N, et al. Cost-effectiveness of breast cancer screening policies using simulation. The Breast. 2015;24(4):440–8.
16. Keen JD, Keen JE. How does age affect baseline screening mammography performance measures? A decision model. BMC Med Inform Decis Mak. 2008. https://doi.org/10.1186/1472-6947-8-40.
17. Wong IO, Kuntz KM, Cowling BJ, Lam CL, Leung GM. Cost-effectiveness of mammography screening for Chinese women. Cancer. 2007;110(4):885–95.
18. Tesfaw A, Demis S, Muniye T, Ashuro Z. Patient delay, and contributing factors among breast cancer patients at two cancer referral centres in Ethiopia: a cross-sectional study. J Multidiscip Healthc. 2020;13:1391–401.
19. Nguyen CP, Adang EMM. Cost-effectiveness of breast cancer screening using mammography in Vietnamese women. PLoS ONE. 2018. https://doi.org/10.1371/journal.pone.0194996.
20. Veniacci M, Calcagno S, Morabito FC. Image contrast enhancement by distances among points in fuzzy hyper-cubes. In: 16th international conference on computer analysis of images and patterns (CAIP); Sep 02–04 2015; Valletta, MALTA. Berlin: Springer, 2015. p. 494–505.
21. Mamo G, Worku A, Lemma S, Demas T. Cost of illness of breast cancer patients on chemotherapy in Addis Ababa Public Hospitals, the case of Tikur Anbessa specialized teaching hospital-cross-sectional types of study. Health Econ Outcome Res Open Access. 2017. https://doi.org/10.4172/2471-268X.1000142.
22. Life tables: The Global Health Observatory. https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/gho-ghe-global-health-estimates-life-tables. Accessed 10 Aug 2021.
23. Marselle E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–24. https://doi.org/10.2471/BLT.14.138206.
24. GDP per capita (current US$)—Ethiopia. World Bank national accounts data, and OECD National Accounts data files. https://data.worldbank.org/indicator/NY.GDP.PCAP.ET. Accessed 3 July 2021.
25. Appiah B. Universal health coverage is still rare in Africa. CMAJ. 2012;184(2):E125–6. https://doi.org/10.1503/cmaj.109-4052.
26. FMOH (Federal Ministry of Health). 2010a. Health Sector Development Program IV: 2010/11–2014/15. Addis Ababa, Ethiopia.
27. FMOH (Federal Ministry of Health) Ethiopia Health Private Sector Assessment; 2019.
28. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening: Preliminary results of a systematic review of the literature. Breast Cancer Res Treat. 1993;25:113–8.
29. O’Donoghue C, Eklund M, Ozanne EM, Esserman LJ. Aggregate cost of mammography screening for Chinese women. Cancer. 2007;110(4):885–95.
30. American Cancer Society recommendations for early breast cancer detection in women without breast symptoms. http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlydetection. Accessed 11 Aug 2021.
31. Jatoi I. Screening clinical breast examination. Surg Clin N Am. 2003;83(4):789–801. https://doi.org/10.1016/S0039-6109(03)00298-8.
32. Ngan TT, Nguyen NTQ, Van Minh H, et al. Effectiveness of clinical breast examination as a ‘stand-alone’ screening modality: an overview of systematic reviews. BMC Cancer. 2020. https://doi.org/10.1186/s12885-020-07521-w.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.